GlassScriptPhysician profile
Christopher Lance Martinez
NPI 1417561895
$5,954.28
in general payments reported to CMS, 2019-2025
29 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $947 · 2022: $1,509 · 2023: $1,292 · 2024: $789 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,497.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,085.07 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $734.46 | 2021-2025 | |
| Lilly USA, LLC | $717.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $652.79 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $435.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $405.83 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $402.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.20 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $163.06 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $137.33 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $135.52 | 2022 | |
| Abbott Laboratories | $131.82 | 2021-2025 | Freestyle Libre, Proclaim |
| Astellas Pharma US INC | $106.54 | 2023-2024 | Veozah |
| Amgen INC. | $91.18 | 2021-2025 | Otezla, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $58.36 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.14 | 2022-2025 | |
| Lundbeck LLC | $48.85 | 2023 | Vyepti |
| Inspire Medical Systems, INC. | $40.70 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $36.76 | 2022-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Eisai INC. | $33.25 | 2021 | |
| Exact Sciences Corporation | $30.40 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $20.96 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.37 | 2022 | |
| Medtronic, INC. | $17.84 | 2025 | Symplicity G3 |
| Teva Pharmaceuticals USA, INC. | $17.04 | 2021 | |
| Olympus America INC. | $16.96 | 2023 | Spiration Valve System |
| Janssen Pharmaceuticals, INC | $15.85 | 2021 | |
| Althera Pharmaceuticals LLC | $15.43 | 2021 | |
| Currax Pharmaceuticals LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.